Design Therapeutics has discovered conjugates consisting of a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence linked to a protein-binding moiety through an oligomeric backbone linker reported to be useful for the treatment of Friedreich ataxia.

Sosei Group Corporation and AbbVie have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological disease.

Oncobix has discovered Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of multiple sclerosis, inflammation, urticaria, systemic lupus erythematosus, allergy, rheumatoid arthritis, asthma and leukemia.

Sequence analysis of 131 human brains has revealed the mutagenesis processes that take place throughout life, from development to senescence. In a new study published in the July 29, 2022, issue of Science, the authors described how high rates of brain somatic mutations (what they call hypermutability) correlated with age. Their work includes certain neuropsychiatric diseases, where they found some genetic signatures that could be used for an early clinical diagnosis of different pathologies.